International Symposium on Supervised Injectable Opioid Assisted Treatment, May 26 and 27 2017, Vancouver, Canada

The International Symposium on Supervised Injectable Opioid Assisted Treatment (iOAT) in Vancouver, Canada, will highlight perspectives from leading authorities from European countries where supervised injectable heroin-assisted treatment is offered to select people affected by opioid dependence.

 
They will discuss the experiences and outcomes from their respective countries including lessons learned. What works? What doesn’t? How do we optimize the outcomes for individuals and for the system? This is a unique opportunity for BC and Canadian health leaders and decision-makers to learn from these experts and have ample opportunity for questions and dialogue.

This event has been organized by the School of Population and Public Health.
 

(Sold out) Symposium date and time:

 
Friday May 26, 2017
8:30 am to 4:15 pm
 

A media briefing with the European experts is scheduled for 12.45 pm in Room 320. Media interested in attending can contact AGibbon@providencehealth.bc.ca or alex.walls@ubc.ca

Location:

Round Dialogue Room
Morris J Wosk Centre for Dialogue
580 W Hastings St, Vancouver, BC

 

Canadian panelists/organizers:

Dr. Eugenia Oviedo-Joekes is an Associate Professor at the School of Population and Public Health at the University of British Columbia, a Research Scientist at the Centre for Health Evaluation and Outcome Sciences, Providence Health Care, a Michael Smith Foundation Scholar and CIHR New Investigator. She has been an investigator in three heroin-assisted trials (one in Spain, two in Canada). She was a co-investigator of North America’s first heroin-assisted treatment trial (NAOMI) and is the Principal Investigator of SALOME, a randomized controlled trial testing medically prescribed injectable hydromorphone and diacetylmorphine (medical grade heroin) for the treatment of severe, long term opioid dependence.
 
Dr. Martin Schechter is a Professor and former Founding Director of the School of Population and Public Health at the University of British Columbia. He co-founded the CIHR Canadian HIV Trials Network, and co-founded the B.C. Centre for Excellence in HIV/AIDS where he served as its first Director of Epidemiology and Population Health. He was the founding President of the Canadian Association for HIV Research, and co-chaired the 1996 International Conference on AIDS in Vancouver. He joined the Michael Smith Foundation for Health Research in 2006 as its first Chief Scientific Officer, and is Co-Director of the recently established Centre for Excellence in Indigenous Health at UBC. Dr. Schechter has authored more than 350 peer-reviewed publications and 590 abstracts and scholarly presentations. He has been invested into the Order of British Columbia and has received the Science Council of British Columbia Gold Medal, fellowship in the Royal Society of Canada and fellowship in the Canadian Academy of Health Sciences.

European guests:

Dr. Robert Haemmig, Swiss Psychiatrist and Director of Integrated and Drug Services, University Psychiatric Services, at the University of Bern, Switzerland
Dr. Robert Haemmig is a Swiss Psychiatrist and Director of Integrated and Drug Services, University Psychiatric Services, at the University of Bern, Switzerland, since 1994. Dr. Haemmig opened the first safer consumption site in Bern in 1986 and was a pioneer in the development and provision of heroin-assisted treatment in Europe. He has been a Member of the Safety Assurance Group for Heroin Prescription in Switzerland since 1996. He is a world authority on innovative harm reduction approaches to injection drug use, patient-centered care and the incorporation of evidence-based approaches into the treatment of addiction. Dr. Haemmig is the founding and past President of the Swiss Society of Addiction Medicine.
 
Dr. Nicola Metrebian, Senior Research Fellow in The National Addiction Centre, Addictions Department, King’s College London, United Kingdom
Dr. Nicola Metrebian is a Senior Research Fellow in The National Addiction Centre, Addictions Department, King’s College London, UK. She has worked in addiction research for over 20 years. She has a background in psychology and a PhD from Imperial College London. She went on to evaluate the clinical and cost effectiveness of supervised heroin treatment for hard to treat heroin users in the UK (Randomised Injectable Opiate Treatment Trial (RIOTT)). More recently, she has managed a programme of research to determine the clinical and cost effectiveness of contingency management in UK addiction treatment services. This included two large cluster trials to improve completion rates of hepatitis B vaccination (CONMAN trial) and to encourage abstinence from street heroin (PRAISE trial) among individuals receiving opiate substitution treatment.
 
Professor Wim van den Brink, Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam, Netherlands
Professor Wim van den Brink is Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He is also Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands. Dr. van den Brink is one of the world’s established experts on the neurobiology and the pharmacological treatment of addiction. His work explores not only the neurobiological research and treatment development of addiction but also the implementation of treatments at the health-services level.
 
Dr. Uwe Verthein, Managing Director at the Centre for Interdisciplinary Addiction Research of Hamburg University (ZIS), Germany
Dr. Uwe Verthein is Managing Director at the Centre for Interdisciplinary Addiction Research of Hamburg University (ZIS). He is responsible for project management and methods in empirical studies. His research interests are directed towards treatment evaluation, monitoring and documentation of addiction treatment as well as (effects of) harm reduction activities. He was involved in the first German Methamphetamine Study and more recently, in evaluation projects on in- and outpatient addiction treatment and rehabilitation. Dr. Verthein was responsible for the design, data management and main analyses of the German randomized trial of heroin-assisted treatment.
 
Dr. Inge Birkemose, Chief physician, heroin assisted treatment at Behandlingscenter Odense, Denmark
Dr. Inge Birkemose received her Medical Degree in 1995 and has practiced with patients receiving opioid maintenance treatments since 1997. She worked as a Medical consultant, OMT at Fyns Amts Behandlingscenter (County of Funen, Denmark). In 2006 she became the Chief physician, Fyns Amts Behandlingscenter (today called Behandlingscenter Odense). Since 2010 she has been the Chief physician, heroin assisted treatment at Behandlingscenter Odense, the largest of the five HAT clinics  in Denmark with some 90 patients. Dr. Birkemose has participated in establishing Denmark’s heroin assisted treatment clinics and in developing guidelines and staff education programs across these clinics. Since 2012 she has served as an Advisor for a Danish National Agency for Patients’ Rights and Complaints in addictions matters, and has served as an advisor on the National Board of Health in addiction matters.

 

No Stone Unturned: The People’s Symposium for Safe Drugs

 
Saturday May 27, 2017
9:30 am to 2:00 pm
 

Location:

Oppenheimer Park
400 Powell St
Vancouver, BC
 
 
This meeting is organized by the Canadian Association of People Who Use Drugs (CAPUD) in partnership with Hives for Humanity and Culture Saves Lives.

This is a community dialogue that will begin with a First Nations cultural opening, followed by a moderated dialogue between people with lived experiences and our European experts. Food and other activities will be available at the park.

This is a public event that does not require registration. Media are welcome to attend.